BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38194683)

  • 1. Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors.
    Veltmaat L; Cortes J
    Blood; 2024 Mar; 143(10):858-865. PubMed ID: 38194683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies.
    Iurlo A; Cattaneo D; Bucelli C; Spallarossa P; Passamonti F
    Curr Treat Options Oncol; 2023 Dec; 24(12):1720-1738. PubMed ID: 38047977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
    Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
    Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
    Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.
    Douxfils J; Haguet H; Mullier F; Chatelain C; Graux C; Dogné JM
    JAMA Oncol; 2016 May; 2(5):625-632. PubMed ID: 26847662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
    Cha SH; Kim K; Song YK
    Acta Oncol; 2023 Dec; 62(12):1767-1774. PubMed ID: 37787749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
    Luciano L; Annunziata M; Attolico I; Di Raimondo F; Maggi A; Malato A; Martino B; Palmieri F; Pane F; Sgherza N; Specchia G
    Eur J Haematol; 2020 Jul; 105(1):3-15. PubMed ID: 32145037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
    Januzzi JL; Garasic JM; Kasner SE; McDonald V; Petrie MC; Seltzer J; Mauro M; Croce K; Berman E; Deininger M; Hochhaus A; Pinilla-Ibarz J; Nicolini F; Kim DW; DeAngelo DJ; Kantarjian H; Xu J; Hall T; Srivastava S; Naranjo D; Cortes J
    J Hematol Oncol; 2022 Jan; 15(1):1. PubMed ID: 34991679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
    Yang J; Surapaneni M; Schiffer CA
    Expert Rev Hematol; 2022 May; 15(5):393-402. PubMed ID: 35544670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
    Miyazaki S
    Rinsho Ketsueki; 2021; 62(8):1024-1028. PubMed ID: 34497188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current perspectives for the treatment of chronic myeloid leukemia.
    Aladağ E; Haznedaroğlu İC
    Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.
    Hirt C; Iannazzo S; Chiroli S; McGarry LJ; le Coutre P; Stenke L; Dahlén T; Lipton JH
    Appl Health Econ Health Policy; 2019 Aug; 17(4):555-567. PubMed ID: 31168745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
    Haddad FG; Issa GC; Jabbour E; Yilmaz M
    Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia.
    Pasvolsky O; Leader A; Iakobishvili Z; Wasserstrum Y; Kornowski R; Raanani P
    Cardiooncology; 2015 Dec; 1(1):5. PubMed ID: 33530148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
    Shoukier M; Kubiak M; Cortes J
    Curr Oncol Rep; 2021 Jun; 23(8):91. PubMed ID: 34125316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
    Takaku T
    Rinsho Ketsueki; 2020; 61(9):1018-1027. PubMed ID: 33162495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.